Home
LGND
LGND News

Latest Ligand Pharmaceuticals Incorporated (LGND) News on November 17, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings

Simply Wall St.

a day ago

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings

Ligand to Present at Stifel 2024 Healthcare Conference

Business Wire

3 days ago

Ligand to Present at Stifel 2024 Healthcare Conference

Argus Research

5 days ago

LGND: Raising target price to $127.00

LGND: 3Q Sales Surprise to the Upside

Zacks Small Cap Research

6 days ago

LGND: 3Q Sales Surprise to the Upside

Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

8 days ago

Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price

Simply Wall St.

9 days ago

Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price

Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com

9 days ago

Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

MT Newswires

10 days ago

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires

10 days ago

Ligand Shares Rise After Q3 Tops Expectations, Guidance Raised

Associated Press Finance

10 days ago

Ligand: Q3 Earnings Snapshot

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Business Wire

10 days ago

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Ligand Pharmaceuticals Inc (LGND) Q3 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

11 days ago

Ligand Pharmaceuticals Inc (LGND) Q3 2024: Everything You Need To Know Ahead Of Earnings

Argus Research

12 days ago

LGND: Lowering target price to $117.00

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Business Wire

16 days ago

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Business Wire

25 days ago

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

GlobeNewswire

a month ago

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...

GuruFocus.com

a month ago

Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...

LGND: Initiating Coverage – A Prince Among Royalty

Zacks Small Cap Research

a month ago

LGND: Initiating Coverage – A Prince Among Royalty

Argus Research

a month ago

LGND: Raising target price to $108.00

MT Newswires

a month ago

Oppenheimer Initiates Ligand Pharmaceuticals at Outperform With $135 Price Target

Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum?

Simply Wall St.

2 months ago

Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum?

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Business Wire

2 months ago

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Argus Research

3 months ago

LGND: Raising target price to $112.00

Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...

GuruFocus.com

3 months ago

Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...

Argus Research

3 months ago

LGND: Raising target price to $110.00

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

Business Wire

3 months ago

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings

Simply Wall St.

3 months ago

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings

Private Capital's Strategic Moves Highlight Ligand Pharmaceuticals in Q2 2024

GuruFocus.com

3 months ago

Private Capital's Strategic Moves Highlight Ligand Pharmaceuticals in Q2 2024

MT Newswires

3 months ago

Ligand Pharmaceuticals Insider Sold Shares Worth $1,797,133, According to a Recent SEC Filing

Insider Buying: CEO Todd Davis Acquires Shares of Ligand Pharmaceuticals Inc (LGND)

GuruFocus.com

3 months ago

Insider Buying: CEO Todd Davis Acquires Shares of Ligand Pharmaceuticals Inc (LGND)

Ligand Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

3 months ago

Ligand Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

MT Newswires

3 months ago

Ligand Pharmaceuticals Q2 Adjusted Earnings Fall, Revenue Increases; Reaffirms Full-Year Guidance

How These Two Lesser-Known Biotech Names Obliterated Sales Expectations

Investor's Business Daily

3 months ago

How These Two Lesser-Known Biotech Names Obliterated Sales Expectations

Associated Press Finance

3 months ago

Ligand: Q2 Earnings Snapshot

Ligand Reports Second Quarter 2024 Financial Results

Business Wire

3 months ago

Ligand Reports Second Quarter 2024 Financial Results

MT Newswires

3 months ago

Ligand Pharmaceuticals COO Matthew Korenberg to Step Down

Hidden Gems Undiscovered Companies with Strong Fundamentals For July 2024

Simply Wall St.

4 months ago

Hidden Gems Undiscovered Companies with Strong Fundamentals For July 2024

Undiscovered Gems In The United States For July 2024

Simply Wall St.

4 months ago

Undiscovered Gems In The United States For July 2024

MT Newswires

4 months ago

RBC Initiates Ligand Pharmaceuticals at Outperform With $130 Price Target

Argus Research

4 months ago

LGND: Raising target price to $107.00

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

Business Wire

4 months ago

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

Argus Research

4 months ago

LGND: Raising target price to $104.00

Argus Research

4 months ago

LGND: Raising target price to $96.00

Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m

Pharmaceutical Technology

4 months ago

Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m

MT Newswires

4 months ago

Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties

Ligand to buy Apeiron; Roche reports another TIGIT setback

BioPharma Dive

4 months ago

Ligand to buy Apeiron; Roche reports another TIGIT setback

Ligand to Acquire APEIRON Biologics AG for $100 Million

Business Wire

4 months ago

Ligand to Acquire APEIRON Biologics AG for $100 Million

Argus Research

4 months ago

LGND: Raising target price to $89.00

Lifecore Biomedical Announces Cooperation Agreement with 22NW

GlobeNewswire

5 months ago

Lifecore Biomedical Announces Cooperation Agreement with 22NW

MT Newswires

5 months ago

Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

Business Wire

5 months ago

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

Zacks

5 months ago

Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?

Zacks

5 months ago

Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?

Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics

Zacks

5 months ago

Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics

The past three years for Ligand Pharmaceuticals (NASDAQ:LGND) investors has not been profitable

Simply Wall St.

5 months ago

The past three years for Ligand Pharmaceuticals (NASDAQ:LGND) investors has not been profitable

MT Newswires

5 months ago

Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

Business Wire

5 months ago

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study

Zacks

5 months ago

Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study

Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment

Zacks

5 months ago

Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment

Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro

Zacks

5 months ago

Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro

Shattuck (STTK) Announces Positive Interim Data on Cancer Drug

Zacks

5 months ago

Shattuck (STTK) Announces Positive Interim Data on Cancer Drug

What Makes Ligand (LGND) a New Strong Buy Stock

Zacks

5 months ago

What Makes Ligand (LGND) a New Strong Buy Stock

Why Is Ligand (LGND) Up 4% Since Last Earnings Report?

Zacks

5 months ago

Why Is Ligand (LGND) Up 4% Since Last Earnings Report?

Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect?

Zacks

5 months ago

Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect?

Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why

Zacks

5 months ago

Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why

Ligand to Participate in Upcoming Investor Conferences

Business Wire

6 months ago

Ligand to Participate in Upcoming Investor Conferences

AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030

Zacks

6 months ago

AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030

Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies

Zacks

6 months ago

Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies

PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug

Zacks

6 months ago

PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug

BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why

Zacks

6 months ago

BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why

Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control

Zacks

6 months ago

Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control

Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC

Zacks

6 months ago

Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC

Ionis (IONS), Biogen Down on Ending Development of ALS Drug

Zacks

6 months ago

Ionis (IONS), Biogen Down on Ending Development of ALS Drug

Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus

Zacks

6 months ago

Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus

Vanda (VNDA) Rises on Positive Data From Motion Sickness Study

Zacks

6 months ago

Vanda (VNDA) Rises on Positive Data From Motion Sickness Study

Insider Sale: President & Chief Operating Officer Matthew Korenberg Sells Shares of Ligand ...

GuruFocus.com

6 months ago

Insider Sale: President & Chief Operating Officer Matthew Korenberg Sells Shares of Ligand ...

FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing

Zacks

6 months ago

FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing

Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag

Zacks

6 months ago

Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag

Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals

Zacks

6 months ago

Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals

Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility

Zacks

6 months ago

Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility

Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales

Zacks

6 months ago

Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales

MT Newswires

6 months ago

Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing

Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade

Zacks

6 months ago

Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade

Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine

Zacks

6 months ago

Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

Zacks

6 months ago

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates

Zacks

6 months ago

Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates

Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates

Zacks

6 months ago

Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates

Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates

Zacks

6 months ago

Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates

Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated

Zacks

6 months ago

Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated

Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

6 months ago

Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why

Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues

Zacks

6 months ago

Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

Zacks

6 months ago

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?

Zacks

6 months ago

Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?

Ligand Pharmaceuticals First Quarter 2024 Earnings: EPS: US$4.86 (vs US$2.56 in 1Q 2023)

Simply Wall St.

6 months ago

Ligand Pharmaceuticals First Quarter 2024 Earnings: EPS: US$4.86 (vs US$2.56 in 1Q 2023)

Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss

Zacks

6 months ago

Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss

MT Newswires

6 months ago

Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript

Insider Monkey

6 months ago

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript

Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues

Zacks

6 months ago

Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues

Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates

Zacks

6 months ago

Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates

Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates

Zacks

6 months ago

Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates

Share on Social Networks: